Across its top 20 institutional holders, CELC's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 13/100, avg. turnover score 36/100).
Quarterly Activity
Recent Activity
+$2.4B
Total Buy Value
$2.2B
Total Sell Value
New buy65
Trim80
Add101
Sold out30
166
Net Buyers
110
Net Sellers
Smart Money Convergence
CELC does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.
13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.
Insider Trading (Form 4)
Form 144 Pre-Sale Notices
2
Filings (90d)
$317.75M
Total Est. Value
3.10M shares
Planned Shares
Last Filed 2026-07-14
Filer
Title/Relationship
Filing Date
Planned Shares
Est. Value
667, L.P.
Former Affiliate
2026-07-14
261K shares
$26.79M
Baker Brothers Life Sciences, L.P.
Former Affiliate
2026-07-14
2.84M shares
$290.96M
Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。
On July 14, 2026, Celcuity Inc. announced that the U.S. FDA approved REVTORPYK (gedatolisib) for treating patients with HR+/HER2- locally advanced or metastatic breast cancer who do not have a PIK3CA mutation. The company disclosed this in an 8-K filing.
Celcuity Inc. filed an amendment (Form 8-K/A) to a previously submitted Current Report. The amendment is dated July 14, 2026, but the provided excerpt does not include the revised disclosure. Based on the filed information, this is a routine procedural filing without new material events.
Who are the top institutional investors holding CELCUITY INC (CELC)?
Major stakeholders currently include Baker Bros. Advisors LP ($903.5M), Avoro Capital Advisors LLC ($388.3M), Perceptive Advisors LLC ($356.9M). Based on the latest 13F filings, there are a total of 278 tracked investment funds and institutions maintaining positions in CELC.
What is the overall institutional sentiment toward CELC recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $883.8M, driven by 166 managers accumulating shares while 110 reduced their exposure.
Which institutions have been selling or reducing their CELC positions?
In the latest period, 80 funds trimmed their holdings, and 30 managers completely exited their positions. The aggregate reported sell value was $2.2B.
Are there any notable investors adding CELC to their portfolios?
Yes, buying activity remains notable. 65 institutions opened new positions in {ticker}, and 101 existing holders added to their shares. The total reported buy value for the quarter amounted to $2.4B.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter